
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2501538/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Privacy in the age of medical big data. Nature Medicine, 2019, 25, 37-43. | 15.2 | 572 |
| 2 | Machine learning in medicine: Addressing ethical challenges. PLoS Medicine, 2018, 15, e1002689. | 3.9 | 351 |
| 3 | Potential Liability for Physicians Using Artificial Intelligence. JAMA - Journal of the American Medical Association, 2019, 322, 1765. | 3.8 | 236 |
| 4 | The Legal And Ethical Concerns That Arise From Using Complex Predictive Analytics In Health Care. Health Affairs, 2014, 33, 1139-1147. | 2.5 | 189 |
| 5 | The need for a system view to regulate artificial intelligence/machine learning-based software as medical device. Npj Digital Medicine, 2020, 3, 53. | 5.7 | 122 |
| 6 | HIPAA and Protecting Health Information in the 21st Century. JAMA - Journal of the American Medical Association, 2018, 320, 231. | 3.8 | 118 |
| 7 | A Framework for Ethical Payment to Research Participants. New England Journal of Medicine, 2018, 378, 766-771. | 13.9 | 111 |
| 8 | Regulatory, safety, and privacy concerns of home monitoring technologies during COVID-19. Nature Medicine, 2020, 26, 1176-1182. | 15.2 | 94 |
| 9 | Potential Legal Liability for Withdrawing or Withholding Ventilators During COVID-19. JAMA - Journal of the American Medical Association, 2020, 323, 1901. | 3.8 | 88 |
| 10 | Beware explanations from AI in health care. Science, 2021, 373, 284-286. | 6.0 | 87 |
| 11 | Big Data, Big Tech, and Protecting Patient Privacy. JAMA - Journal of the American Medical Association, 2019, 322, 1141. | 3.8 | 85 |
| 12 | Digital Smartphone Tracking for COVID-19. JAMA - Journal of the American Medical Association, 2020, 323, 2371. | 3.8 | 83 |
| 13 | Algorithms on regulatory lockdown in medicine. Science, 2019, 366, 1202-1204. | 6.0 | 64 |
| 14 | The Ethics of Smart Pills and Self-Acting Devices: Autonomy, Truth-Telling, and Trust at the Dawn of Digital Medicine. American Journal of Bioethics, 2018, 18, 38-47. | 0.5 | 63 |
| 15 | Transplant Tourism: The Ethics and Regulation of International Markets for Organs. Journal of Law, Medicine and Ethics, 2013, 41, 269-285. | 0.4 | 53 |
| 16 | The European artificial intelligence strategy: implications and challenges for digital health. The Lancet Digital Health, 2020, 2, e376-e379. | 5.9 | 51 |
| 17 | Future-proofing global health: Governance of priorities. Global Public Health, 2018, 13, 519-527. | 1.0 | 50 |
| 18 | Legislation to Criminalize Gender-Affirming Medical Care for Transgender Youth. JAMA - Journal of the American Medical Association, 2021, 325, 2251. | 3.8 | 47 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries. Nature Medicine, 2019, 25, 1198-1204. | 15.2 | 46 |
| 20 | Designing development programs for non-traditional antibacterial agents. Nature Communications, 2019, 10, 3416. | 5.8 | 46 |
| 21 | Universal Masking in the United States. JAMA - Journal of the American Medical Association, 2020, 324, 837. | 3.8 | 44 |
| 22 | Artificial Intelligence and Liability in Medicine: Balancing Safety and Innovation. Milbank Quarterly, 2021, 99, 629-647. | 2.1 | 44 |
| 23 | Transatlantic lessons in regulation of mitochondrial replacement therapy. Science, 2015, 348, 178-180. | 6.0 | 43 |
| 24 | Consensus Statement on Electronic Health Predictive Analytics: A Guiding Framework to Address Challenges. EGEMS (Washington, DC), 2017, 4, 3. | 2.0 | 41 |
| 25 | Digital Health Passes in the Age of COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1933. | 3.8 | 38 |
| 26 | When clinical trials compete: prioritising study recruitment. Journal of Medical Ethics, 2017, 43, 803-809. | 1.0 | 37 |
| 27 | Ethical and legal issues of ingestible electronic sensors. Nature Electronics, 2019, 2, 329-334. | 13.1 | 36 |
| 28 | Ethical and Legal Aspects of Ambient Intelligence in Hospitals. JAMA - Journal of the American Medical Association, 2020, 323, 601. | 3.8 | 36 |
| 29 | The FDA is prohibited from going germline. Science, 2016, 353, 545-546. | 6.0 | 34 |
| 30 | A Fuller Picture of Organ Markets. American Journal of Bioethics, 2014, 14, 19-21. | 0.5 | 33 |
| 31 | How NFTs could transform health information exchange. Science, 2022, 375, 500-502. | 6.0 | 32 |
| 32 | Mitigating Racial Bias in Machine Learning. Journal of Law, Medicine and Ethics, 2022, 50, 92-100. | 0.4 | 31 |
| 33 | HOW TO REGULATE MEDICAL TOURISM (AND WHY IT MATTERS FOR BIOETHICS). Developing World Bioethics, 2012, 12, 9-20. | 0.6 | 30 |
| 34 | Disruptive reproductive technologies. Science Translational Medicine, 2017, 9, . | 5.8 | 30 |
| 35 | Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges. Trends in Biotechnology, 2018, 36, 639-641. | 4.9 | 28 |
| 36 | The Regulation of Mitochondrial Replacement Techniques Around the World. Annual Review of Genomics and Human Genetics, 2020, 21, 565-586. | 2.5 | 28 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Direct-to-consumer medical machine learning and artificial intelligence applications. Nature Machine Intelligence, 2021, 3, 283-287. | 8.3 | 28 |
| 38 | What Makes Artificial Intelligence Exceptional in Health Technology Assessment?. Frontiers in Artificial Intelligence, 2021, 4, 736697. | 2.0 | 26 |
| 39 | Psychedelic therapy: a roadmap for wider acceptance and utilization. Nature Medicine, 2021, 27, 1669-1671. | 15.2 | 25 |
| 40 | Building Capacity for a Global Genome Editing Observatory: Institutional Design. Trends in Biotechnology, 2018, 36, 741-743. | 4.9 | 23 |
| 41 | Medical Tourism: The View from Ten Thousand Feet. Hastings Center Report, 2010, 40, 11-12. | 0.7 | 22 |
| 42 | Ethical and Legal Implications of Remote Monitoring of Medical Devices. Milbank Quarterly, 2020, 98, 1257-1289. | 2.1 | 20 |
| 43 | The Interstate Medical Licensure Compact. JAMA - Journal of the American Medical Association, 2021, 325, 1607. | 3.8 | 20 |
| 44 | How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?. Journal of Nuclear Medicine, 2021, 62, 15-16. | 2.8 | 20 |
| 45 | Going Germline: Mitochondrial Replacement as a Guide to Genome Editing. Cell, 2016, 164, 832-835. | 13.5 | 18 |
| 46 | Preventing Mitochondrial Diseases: Embryo-Sparing Donor-Independent Options. Trends in Molecular Medicine, 2018, 24, 449-457. | 3.5 | 18 |
| 47 | Medical Malpractice and Black-Box Medicine. , 0, , 295-306. | | 18 |
| 48 | Human Embryonic Stem-Cell Research under Siege — Battle Won but Not the War. New England Journal of Medicine, 2011, 364, e48. | 13.9 | 17 |
| 49 | Heritable Human Genome Editing: The Public Engagement Imperative. CRISPR Journal, 2020, 3, 434-439. | 1.4 | 17 |
| 50 | The Supreme Court, the Texas Abortion Law (SB8), and the Beginning of the End of <i>Roe v Wade</i> ?. JAMA - Journal of the American Medical Association, 2021, 326, 1473. | 3.8 | 16 |
| 51 | Patientâ€Centered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues. IRB: Ethics & Human Research, 2018, 40, 7-17. | 0.8 | 15 |
| 52 | The mHealth Power Paradox. , 2022, , 63-76. | | 14 |
| 53 | What Overturning <i>Roe v Wade</i> May Mean for Assisted Reproductive Technologies in the US. JAMA - Journal of the American Medical Association, 2022, 328, 15. | 3.8 | 14 |
| 54 | Reconsideration of the Lifetime Ban on Blood Donation by Men Who Have Sex With Men. JAMA - Journal of the American Medical Association, 2014, 312, 337. | 3.8 | 13 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Is There a Duty to Share Healthcare Data?. , 0, , 209-222. | | 13 |
| 56 | Artificial Wombs and Abortion Rights. Hastings Center Report, 2017, 47, inside back cover. | 0.7 | 12 |
| 57 | Medical Crowdfunding for Unproven Medical Treatments: Should Gofundme Become a Gatekeeper?. Hastings Center Report, 2019, 49, 32-38. | 0.7 | 12 |
| 58 | Ethical and Legal Challenges of Artificial Intelligence-Driven Health Care. SSRN Electronic Journal, 0, , | 0.4 | 12 |
| 59 | Al, Explainability, and Safeguarding Patient Safety in Europe. , 2022, , 91-102. | | 12 |
| 60 | Fetal Pain, Abortion, Viability, and the Constitution. Journal of Law, Medicine and Ethics, 2011, 39, 235-242. | 0.4 | 11 |
| 61 | Can the Government Ban Organ Sale? Recent Court Challenges and the Future of US Law on Selling Human Organs and Other Tissue. American Journal of Transplantation, 2012, 12, 1983-1987. | 2.6 | 11 |
| 62 | Made-to-Order Embryos for Sale — A Brave New World?. New England Journal of Medicine, 2013, 368, 2517-2519. | 13.9 | 11 |
| 63 | How does emerging patent case law in the US and Europe affect precision medicine?. Nature Biotechnology, 2019, 37, 1118-1125. | 9.4 | 11 |
| 64 | Ensuring Patient Safety and Benefit in Use of Medical Devices Granted Expedited Approval. , 2022, , 217-228. | | 11 |
| 65 | Disrupting the Market for Ineffective Medical Devices. , 2022, , 179-191. | | 11 |
| 66 | Volume Introduction. , 2022, , 1-10. | | 11 |
| 67 | Professional Self-Regulation in Medicine. , 2022, , 244-255. | | 11 |
| 68 | Hospital-Based Active Shooter Incidents. JAMA - Journal of the American Medical Association, 2015, 313, 1209. | 3.8 | 10 |
| 69 | Preventing Mitochondrial DNA Diseases. JAMA - Journal of the American Medical Association, 2016, 316, 273. | 3.8 | 10 |
| 70 | Your Money or Your Patient's Life? Ransomware and Electronic Health Records. Annals of Internal Medicine, 2017, 167, 587. | 2.0 | 10 |
| 71 | In support of mitochondrial replacement therapy. Nature Medicine, 2019, 25, 870-871. | 15.2 | 10 |
| 72 | When science and politics collide: Enhancing the FDA. Science, 2019, 364, 628-631. | 6.0 | 10 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Physicians, Medical Ethics, and Execution by Lethal Injection. JAMA - Journal of the American Medical Association, 2014, 311, 2375. | 3.8 | 9 |
| 74 | Inbound medical tourism to Barbados: a qualitative examination of local lawyers' prospective legal and regulatory concerns. BMC Health Services Research, 2015, 15, 291. | 0.9 | 9 |
| 75 | Clinical decision making regarding suicide risk: Effect of patient and clinician age. Death Studies, 2016, 40, 269-274. | 1.8 | 9 |
| 76 | Mitchochondrial replacement therapy: the IOM report and its aftermath. Nature Reviews Genetics, 2016, 17, 189-190. | 7.7 | 9 |
| 77 | Big Data and Intellectual Property Rights in the Health and Life Sciences. , 0, , 311-323. | | 9 |
| 78 | Mitochondrial disease: Replace or edit?. Science, 2021, 373, 1200-1201. | 6.0 | 9 |
| 79 | Sharing Clinical Notes. JAMA - Journal of the American Medical Association, 2022, 327, 717. | 3.8 | 9 |
| 80 | Ethics-by-design: efficient, fair and inclusive resource allocation using machine learning. Journal of Law and the Biosciences, 2022, 9, Isac012. | 0.8 | 9 |
| 81 | Skating the line between general wellness products and regulated devices: strategies and implications. Journal of Law and the Biosciences, 2022, 9, . | 0.8 | 9 |
| 82 | Supreme Court Ruling on the Texas Abortion Law. JAMA - Journal of the American Medical Association, 2022, 327, 621. | 3.8 | 8 |
| 83 | Stem Cell-Derived Human Gametes: The Public Engagement Imperative. Trends in Molecular Medicine, 2019, 25, 165-167. | 3.5 | 7 |
| 84 | Emerging Ethical Considerations for the Use of Artificial Intelligence inÂOphthalmology. Ophthalmology Science, 2022, 2, 100141. | 1.0 | 7 |
| 85 | Making Residency Work Hour Rules Work. Journal of Law, Medicine and Ethics, 2013, 41, 310-314. | 0.4 | 6 |
| 86 | Medical Tourism, Medical Migration, and Global Justice: Implications for Biosecurity in a Globalized World. Medical Law Review, 2017, 25, 200-222. | 0.2 | 6 |
| 87 | Mitochondrial replacement therapy: born in the USA: theÂuntold story of a conceptual breakthrough. American Journal of Obstetrics and Gynecology, 2017, 217, 561-563. | 0.7 | 6 |
| 88 | Heritable Human Genome Editing. JAMA - Journal of the American Medical Association, 2020, 324, 1941. | 3.8 | 6 |
| 89 | IRB Oversight of Patient-Centered Outcomes Research: A National Survey of IRB Chairpersons. Journal of Empirical Research on Human Research Ethics, 2018, 13, 421-431. | 0.6 | 6 |
| 90 | Patient-Centered Outcomes Research: Stakeholder Perspectives and Ethical and Regulatory Oversight Issues. IRB: Ethics & Human Research, 2018, 40, 7-17. | 0.8 | 6 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | The Pandemic Preparedness Program. JAMA - Journal of the American Medical Association, 2022, , . | 3.8 | 6 |
| 92 | The hospital-at-home presents novel liabilities for physicians, hospitals, caregivers, and patients. Nature Medicine, 2022, 28, 438-441. | 15.2 | 6 |
| 93 | Selling Bone Marrow — <i>Flynn v. Holder</i> . New England Journal of Medicine, 2012, 366, 296-297. | 13.9 | 5 |
| 94 | The Ethics of Heritable Genome Editing. JAMA - Journal of the American Medical Association, 2018, 320, 2531. | 3.8 | 5 |
| 95 | Personhood and the Three Branches of Government. New England Journal of Medicine, 2018, 378, 2453-2455. | 13.9 | 5 |
| 96 | Regulation of Stem Cell Therapy Travel. Current Stem Cell Reports, 2018, 4, 220-227. | 0.7 | 5 |
| 97 | How bans on germline editing deprive patients with mitochondrial disease. Nature Biotechnology, 2019, 37, 589-592. | 9.4 | 5 |
| 98 | Legal and Ethical Issues in the Report <i>Heritable Human Genome Editing</i> . Hastings Center Report, 2021, 51, 8-12. | 0.7 | 5 |
| 99 | At-home Diagnostics and Diagnostic Excellence. JAMA - Journal of the American Medical Association, 2022, 327, 523. | 3.8 | 5 |
| 100 | SARS-CoV-2 Laboratory-Developed Tests. JAMA - Journal of the American Medical Association, 2022, 327, 1229. | 3.8 | 5 |
| 101 | The End of <i>Roe v Wade</i> and New Legal Frontiers on the Constitutional Right to Abortion. JAMA - Journal of the American Medical Association, 2022, 328, 325. | 3.8 | 5 |
| 102 | S.H. and Others v. Austria and circumvention tourism. Reproductive BioMedicine Online, 2012, 25, 660-662. | 1.1 | 4 |
| 103 | Effect of a legal prime on clinician's assessment of suicide risk. Death Studies, 2016, 40, 61-67. | 1.8 | 4 |
| 104 | Truth in Advertising: Disclosure of Participant Payment in Research Recruitment Materials. Therapeutic Innovation and Regulatory Science, 2018, 52, 268-274. | 0.8 | 4 |
| 105 | Preventing Mitochondrial Disease. Obstetrics and Gynecology, 2018, 131, 553-556. | 1.2 | 4 |
| 106 | Big Data's New Discrimination Threats. , 0, , 85-97. | | 4 |
| 107 | Avoiding Overregulation in the Medical Internet of Things. , 0, , 129-141. | | 4 |
| 108 | Gene Editing Sperm and Eggs (not Embryos). Journal of Law, Medicine and Ethics, 2020, 48, 619-621. | 0.4 | 4 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Algorithmic Disability Discrimination. , 2020, , 242-254. | | 4 |
| 110 | Disruptive Synergy: Melding of Human Genetics and Clinical Assisted Reproduction. Cell Reports Medicine, 2020, 1, 100093. | 3.3 | 4 |
| 111 | Therapeutic Germline Editing: Sense and Sensibility. Trends in Genetics, 2020, 36, 315-317. | 2.9 | 4 |
| 112 | Commentary on â€~Gestation, Equality and Freedom: Ectogenesis as a Political Perspective'. Journal of Medical Ethics, 2020, 46, 87-88. | 1.0 | 4 |
| 113 | Enforcement of the Physician Payments Sunshine Act. JAMA - Journal of the American Medical Association, 2021, 326, 807. | 3.8 | 4 |
| 114 | The next two decades of mifepristone at FDA: History as destiny,. Contraception, 2022, 109, 1-7. | 0.8 | 4 |
| 115 | Deadly Legacy—The 510(k) Path to Medical Device Clearance. JAMA Surgery, 2022, 157, 185. | 2.2 | 4 |
| 116 | Who will oversee the ethical limits of human embryo research?. Nature Biotechnology, 2022, 40, 463-464. | 9.4 | 4 |
| 117 | "l'd feel like someone was watchin' me… watching for a good reason― perceptions of data privacy, access, and sharing in the context of real-time PrEP adherence monitoring among HIV-negative MSM with substance use. AIDS and Behavior, 2022, 26, 2981-2993. | 1.4 | 4 |
| 118 | How Much May Religious Accommodations Burden Others?. , 0, , 215-229. | | 3 |
| 119 | A Common Law Duty to Disclose Conscience-Based Limitations on Medical Practice. , 2017, , 187-197. | | 3 |
| 120 | Correlation versus Causation in Health-Related Big Data Analysis. , 0, , 42-55. | | 3 |
| 121 | Who's Left Out of Big Data?. , 0, , 98-111. | | 3 |
| 122 | Losing Embryos, Finding Justice: Life, Liberty, and the Pursuit of Personhood. Annals of Internal Medicine, 2018, 169, 800. | 2.0 | 3 |
| 123 | Healthcare As Eugenics. , 2020, , 20-32. | | 3 |
| 124 | What would responsible remedial human germline editing look like?. Nature Biotechnology, 2020, 38, 398-400. | 9.4 | 3 |
| 125 | The Myth of "Anonymous―Gamete Donation in the Age of Direct-to-Consumer Genetic Testing. , 2021, , 93-106. | | 3 |
| 126 | Prohibiting Anonymous Sperm Donation and the Child Welfare Error. Hastings Center Report, 2011, 41, 13-14. | 0.7 | 2 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | The Constitutionality of the ACA's Medicaid-Expansion Mandate. New England Journal of Medicine, 2012, 366, 103-104. | 13.9 | 2 |
| 128 | Sherley v Sebelius and the Future of Stem Cell Research. JAMA - Journal of the American Medical Association, 2012, 308, 2087. | 3.8 | 2 |
| 129 | This Is Your Brain on Human Rights: Moral Enhancement and Human Rights. Law and Ethics of Human Rights, 2015, 9, 1-41. | 0.4 | 2 |
| 130 | Religious Outliers. , 2017, , 173-186. | | 2 |
| 131 | Religion and Reproductive Technology. , 2017, , 360-371. | | 2 |
| 132 | Big Data's Epistemology and Its Implications for Precision Medicine and Privacy. , 0, , 30-41. | | 2 |
| 133 | Big Data and Regulatory Arbitrage in Healthcare. , 0, , 56-68. | | 2 |
| 134 | Thought-Leader Perspectives on Risks in Precision Medicine Research. , 0, , 161-174. | | 2 |
| 135 | Big Data, HIPAA, and the Common Rule. , 0, , 251-264. | | 2 |
| 136 | Humanizing Clinical Care for Patients with Disabilities. , 2020, , 117-128. | | 2 |
| 137 | Measuring Health-State Utility via Cured Patients. , 2020, , 266-280. | | 2 |
| 138 | Judicial Representation: Speaking for Others from the Bench. , 2020, , 211-220. | | 2 |
| 139 | The Down Syndrome Information Act and "Mere Difference†Redefining the Scope of Prenatal Testing Conversations?. , 2020, , 64-76. | | 2 |
| 140 | Reproduction reimagined. F&S Reports, 2020, 1, 7-8. | 0.4 | 2 |
| 141 | CRISPR immunity: a case study for justified somatic genetic modification?. Journal of Medical Ethics, 2022, 48, 83-85. | 1.0 | 2 |
| 142 | Industry-Sponsored Speaker Programs—End of the Line?. JAMA - Journal of the American Medical Association, 2021, 325, 1835. | 3.8 | 2 |
| 143 | Governing Human Germline Editing Through Patent Law. JAMA - Journal of the American Medical Association, 2021, 326, 1149. | 3.8 | 2 |
| 144 | The Affordable Care Act Resurrected. JAMA - Journal of the American Medical Association, 2021, 326, 1797-1798. | 3.8 | 2 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Beyond Security Patches—Fundamental Incentive Problems in Health Care Cybersecurity. JAMA Health Forum, 2021, 2, e212969. | 1.0 | 2 |
| 146 | Product Liability Suits for FDA-Regulated AI/ML Software. , 2022, , 22-35. | | 2 |
| 147 | The Interaction of the Medical Device Regulation and the GDPR. , 2022, , 77-90. | | 2 |
| 148 | Of Modest Proposals and Non-Identity: A Comment on the Right to Know Your Genetic Parents. American Journal of Bioethics, 2013, 13, 45-47. | 0.5 | 1 |
| 149 | Plan B: access to emergency contraception in the legal and political cross hairs. Contraception, 2013, 88, 477-480. | 0.8 | 1 |
| 150 | Clinical Trials and the Right to Remain Silent. JAMA Internal Medicine, 2014, 174, 1505. | 2.6 | 1 |
| 151 | Medical tourism for services illegal in patients' home country. , 2015, , . | | 1 |
| 152 | Influence, integrity, and the FDA: An ethical framework. Science, 2017, 357, 876-877. | 6.0 | 1 |
| 153 | Brain Death Rejected. , 2017, , 293-305. | | 1 |
| 154 | Reclaiming Biopolitics: Religion and Psychiatry in the Sexual Orientation Change Therapy Cases and the Establishment Clause Defense. , 0, , 276-288. | | 1 |
| 155 | On Scarcity and the Value of Clinical Trials. American Journal of Bioethics, 2018, 18, 71-73. | 0.5 | 1 |
| 156 | Big Data and Individual Autonomy in a Crowd. , 0, , 19-29. | | 1 |
| 157 | The Future of Pharmacovigilance. , 0, , 73-84. | | 1 |
| 158 | The Common Rule and Research with Data, Big and Small. , 0, , 237-250. | | 1 |
| 159 | Big Data and Human Medical Judgment. , 0, , 283-294. | | 1 |
| 160 | The Pathologies of Data-Generating Patents. , 0, , 324-336. | | 1 |
| 161 | The Law and Ethics of Fetal Burial Requirements for Reproductive Health Care. JAMA - Journal of the American Medical Association, 2019, 322, 1347. | 3.8 | 1 |
| 162 | The European Medicines Agency's Approach to Transparency. , 2019, , 210-226. | | 1 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Smashing into Windows. , 2019, , 17-29. | | 1 |
| 164 | Is Pharmaceutical Price Transparency an Effective Means to Reduce High Prices and Wide Variations?. , 2019, , 132-152. | | 1 |
| 165 | Using Disclosure to Regulate PBMs. , 2019, , 343-356. | | 1 |
| 166 | Price Transparency., 2019, , 153-164. | | 1 |
| 167 | A Troubling Court Decision for Reproductive Rights. JAMA - Journal of the American Medical Association, 2019, 322, 23. | 3.8 | 1 |
| 168 | Private Rights and the Public Interest in Drug and Medical Device Litigation. JAMA Internal Medicine, 2020, 180, 299. | 2.6 | 1 |
| 169 | The Privacy Problem in Disability Antidiscrimination Law. , 2020, , 159-170. | | 1 |
| 170 | Dementia, Disability, and Advance Medical Directives: Defensible Standards for Dementia Care. , 2020, , 77-88. | | 1 |
| 171 | Expressing Respect for People with Disabilities in Medical Practice. , 2020, , 93-103. | | 1 |
| 172 | Chronic Pain As a Challenge for Disability Theory and Policy. , 2020, , 129-140. | | 1 |
| 173 | Disability, Health, and Normal Function. , 2020, , 5-19. | | 1 |
| 174 | HIPAA in the Era of Data Sharing—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 477. | 3.8 | 1 |
| 175 | The American Rescue Plan Act of 2021. JAMA - Journal of the American Medical Association, 2021, 326, 27-28. | 3.8 | 1 |
| 176 | In Favor of an Action for Genetic Conversion. , 2021, , 39-50. | | 1 |
| 177 | Noninvasive Prenatal Genome Sequencing. , 2021, , 81-92. | | 1 |
| 178 | An Ethical Framework for Genetic Counseling in the Genomic Era. , 2021, , 233-245. | | 1 |
| 179 | Governing Nontraditional Gene Editing. , 2021, , 145-156. | | 1 |
| 180 | When Failure Is Not an Option: The Independent Panel Pandemic Report. American Journal of Medicine, 2022, 135, 131-132. | 0.6 | 1 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Liability Implications of Direct-to-Consumer Genetic Testing. , 2021, , 15-25. | | 1 |
| 182 | Regulatory and Medical Aspects of DTC Genetic Testing. , 2021, , 277-292. | | 1 |
| 183 | An Overdue Executive Order: Reinstating the National Bioethics Commission. American Journal of Medicine, 2021, 134, 1199-1200. | 0.6 | 1 |
| 184 | June Medical Services v Russo—the Future of Abortion Access in the US. JAMA Health Forum, 2020, 1, e201107. | 1.0 | 1 |
| 185 | Transparency and the Doctor–Patient Relationship — Rethinking Conflict-of-Interest Disclosures. New England Journal of Medicine, 2022, 386, 300-302. | 13.9 | 1 |
| 186 | Germ-Line Gene Editing and Congressional Reaction in Context: Learning From Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs. Journal of Law and Health, 2017, 30, 20-54. | 0.2 | 1 |
| 187 | Regulating Posttrial Access to In-Dwelling Class III Neural Devices. , 2022, , 256-267. | | 1 |
| 188 | Cybersecurity of Medical Devices. , 2022, , 51-62. | | 1 |
| 189 | Regulating Devices that Create Life. , 2022, , 203-214. | | 1 |
| 190 | Regulation of Digital Health Technologies in the European Union. , 2022, , 103-114. | | 1 |
| 191 | Are Electronic Health Records Medical Devices?. , 2022, , 36-46. | | 1 |
| 192 | Not Your Father's Religious Exemptions: The Contraceptive- Coverage Litigation and the Rights of Others. , 0, , 60-74. | | 0 |
| 193 | Unpacking the Relationship Between Conscience and Access. , 0, , 242-258. | | О |
| 194 | Accommodating Miracles: Medical Futility and Religious Free Exercise. , 0, , 306-318. | | 0 |
| 195 | RELIGION AND REPRODUCTIVE HEALTH CARE: INTRODUCTION. , 0, , 345-347. | | Ο |
| 196 | Contracting Religion. , 0, , 113-124. | | 0 |
| 197 | Introduction: Law, Religion, and Health in the United States. , 0, , 1-18. | | 0 |
| 198 | LAW, RELIGION, AND HEALTH CARE INSTITUTIONS: INTRODUCTION. , 0, , 87-89. | | 0 |

| # | Article | IF | CITATIONS |
|-----|---|----|-----------|
| 199 | Mission Integrity Matters: Balancing Catholic Health Care Values and Public Mandates. , 0, , 125-138. | | Ο |
| 200 | Bosses in the Bedroom: Religious Employers and the Future of Employer- Sponsored Health Care. , 0, , 154-168. | | 0 |
| 201 | PROFESSIONAL RESPONSIBILITIES, RELIGION, AND HEALTH CARE: INTRODUCTION. , 0, , 169-172. | | Ο |
| 202 | Religious Convictions About Homosexuality and the Training of Counseling Professionals: How Should We Treat Religious- Based Opposition to Counseling About Same- Sex Relationships?. , 0, , 263-275. | | 0 |
| 203 | Religion and the Unborn Under the First Amendment. , 0, , 372-382. | | Ο |
| 204 | Race, Religion, and Masculinity: The HIV Double Bind. , 0, , 387-398. | | 0 |
| 205 | Religious Liberty, Health Care, and the Culture Wars. , 0, , 21-33. | | Ο |
| 206 | Religious Exemptions to the Individual Mandate: Health Care Sharing Ministries and the Affordable Care Act. , 0, , 143-153. | | 0 |
| 207 | A Corporation's Exercise of Religion: A Practitioner's Experience. , 0, , 90-102. | | Ο |
| 208 | "A Patchwork Array of Theocratic Fiefdoms?―RFRA Claims Against the ACA's Contraception Mandate as Examples of the New Feudalism. , 0, , 230-241. | | 0 |
| 209 | The HHS Mandate Litigation and Religious Health Care Providers. , 0, , 47-59. | | Ο |
| 210 | Recent Applications of the Supreme Court's Hands- Off Approach to Religious Doctrine: From Hosanna- Tabor and Holt to Hobby Lobby and Zubik. , 0, , 75-86. | | 0 |
| 211 | A CASE STUDY – RELIGIOUS BELIEFS AND THE HEALTH OF THE LGBT COMMUNITY: INTRODUCTION. , 0, , 259-262. | | 0 |
| 212 | When Religion Pollutes: How Should Law Respond When Religious Practice Threatens Public Health?. , 0, , 411-422. | | 0 |
| 213 | From Smith to Hobby Lobby : The Transformation of the Religious Freedom Restoration Act. , 0, , 34-46. | | 0 |
| 214 | The Natural Person as the Limiting Principle for Conscience: Can a Corporation Have a Conscience If It Doesn't Have an Intellect and Will?. , 0, , 103-112. | | 0 |
| 215 | Conscientious Objection, Complicity, and Accommodation. , 0, , 203-214. | | 0 |
| 216 | Putting the Insanity Defense on Trial: Understanding Criminality in the Context of Religion and Mental Illness. , 0, , 319-331. | | 0 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Religion as a Controlling Interference in Medical Decision Making by Minors. , 0, , 332-344. | | 0 |
| 218 | Regulating Reasons: Governmental Regulation of Private Deliberation in Reproductive Decision Making. , 0, , 348-359. | | 0 |
| 219 | RELIGION, LAW, AND PUBLIC HEALTH: INTRODUCTION. , 0, , 383-386. | | Ο |
| 220 | The Intersection of Law, Religion, and Infectious Disease in the Handling and Disposition of Human Remains. , 0, , 399-410. | | 0 |
| 221 | Potential Roadblocks in Healthcare Big Data Collection. , 0, , 112-124. | | 0 |
| 222 | Data Policy for Internet of Things Healthcare Devices. , 0, , 142-156. | | 0 |
| 223 | From Individual to Group Privacy in Biomedical Big Data. , 0, , 175-192. | | 0 |
| 224 | Big Data and Informed Consent. , 0, , 193-204. | | 0 |
| 225 | Societal Lapses in Protecting Individual Privacy, the Common Rule, and Big Data Health Research. , 0, , 223-236. | | 0 |
| 226 | Data Sharing that Enables Postapproval Drug and Device Research and Protects Patient Privacy. , 0, , 269-282. | | 0 |
| 227 | The Lumbering Crawl Toward Human Germline Editing. Journal of Law, Medicine and Ethics, 2018, 46, 1010-1012. | 0.4 | 0 |
| 228 | Nontransparency in Electronic Health Record Systems. , 2019, , 273-285. | | 0 |
| 229 | The Interplay of Privacy and Transparency in Health Care. , 2019, , 30-43. | | Ο |
| 230 | Transparency Trade-offs. , 2019, , 44-57. | | 0 |
| 231 | Slightly Hazy. , 2019, , 58-68. | | 0 |
| 232 | Transparency versus Informed Consent. , 2019, , 75-87. | | 0 |
| 233 | Transparency and Financial Conflicts. , 2019, , 88-102. | | 0 |
| 234 | Making Religion Transparent. , 2019, , 103-114. | | 0 |

| # | Article | IF | CITATIONS |
|-----|--|----|-----------|
| 235 | Transparency on Prescription Drug Research Expenditures. , 2019, , 121-131. | | 0 |
| 236 | Solving Surprise Medical Bills. , 2019, , 165-178. | | 0 |
| 237 | Increasing the Transparency of FDA Review to Enhance the Innovation Process. , 2019, , 185-195. | | 0 |
| 238 | Transparency and Clinical Trial Data Sharing. , 2019, , 196-209. | | 0 |
| 239 | Introduction to Part V. , 2019, , 229-232. | | 0 |
| 240 | The Role of Transparency in Promoting Healthy Behaviors. , 2019, , 233-243. | | 0 |
| 241 | The Role of Transparency in Patient Safety Improvement. , 2019, , 244-259. | | 0 |
| 242 | Personal Health Records as a Tool for Transparency in Health Care. , 2019, , 260-272. | | 0 |
| 243 | Transparency Challenges in Reproductive Health Care. , 2019, , 286-296. | | 0 |
| 244 | Introduction to Part VI. , 2019, , 299-300. | | 0 |
| 245 | ERISA as a Barrier for State Health Care Transparency Efforts. , 2019, , 301-313. | | 0 |
| 246 | Transparency and Data Sharing in Clinical Research and Big Pharma. , 2019, , 314-328. | | 0 |
| 247 | Promoting IRB Transparency. , 2019, , 329-342. | | 0 |
| 248 | Making "Meaningful Access―Meaningful: Equitable Healthcare for Divisive Times. , 2020, , 147-158. | | 0 |
| 249 | Sexual Agency As a Rights-Based Imperative for Persons with Intellectual Disabilities. , 2020, , 171-182. | | 0 |
| 250 | Destigmatizing Disability in the Law of Immigration Admissions. , 2020, , 187-199. | | 0 |
| 251 | Can We Universally Accommodate Mental Health and Should We? A Systematic Review of the Evidence and Ethical Analysis. , 2020, , 227-241. | | 0 |
| 252 | The Pathways Approach to Priority Setting: Considering Quality of Life While Being Fair to Individuals with Disabilities. , 2020, , 255-265. | | 0 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Introduction to Part V. , 2020, , 185-186. | | Ο |
| 254 | The Normative Bases of Medical Civil Rights. , 2020, , 200-210. | | 0 |
| 255 | Introduction to Part VI. , 2020, , 223-226. | | 0 |
| 256 | Disabled Bodies and Good Organs. , 2020, , 104-116. | | 0 |
| 257 | The Case for Remedial Germline Editing—The Long-term View. JAMA - Journal of the American Medical Association, 2020, 323, 1762. | 3.8 | 0 |
| 258 | Abortion, the Disabilities of Pregnancy, and the Dignity of Risk. , 2020, , 51-63. | | 0 |
| 259 | Preventing Female Genital Mutilation in the United States: The Legal Threat to Effective Action. American Journal of Public Health, 2020, 110, 813-814. | 1.5 | ο |
| 260 | Epistemic Injustice, Disability Stigma, and Public Health Law. , 2020, , 33-46. | | 0 |
| 261 | Genetic Paparazzi. , 2021, , 113-124. | | Ο |
| 262 | Introduction to Part V. , 2021, , 231-232. | | 0 |
| 263 | Consuming Genetics As a Life Insurance Consumer. , 2021, , 26-38. | | Ο |
| 264 | Governance in the Era of CRISPR and DIY-Bio. , 2021, , 65-76. | | 0 |
| 265 | Generational Failures of Law and Ethics. , 2021, , 173-185. | | Ο |
| 266 | Precision Medicine and the Resurgence of Race in Genomic Medicine. , 2021, , 186-197. | | 0 |
| 267 | Physician-Mediated Elective Whole Genome Sequencing Tests. , 2021, , 246-259. | | 0 |
| 268 | Programming Our Genomes, Programming Ourselves. , 2021, , 129-144. | | 0 |
| 269 | Privacy Best Practices for Direct-to-Consumer Genetic Testing Services. , 2021, , 260-276. | | Ο |
| 270 | Direct-to-Consumer Genomics and Personal Health Data. , 2021, , 51-64. | | 0 |

| # | Article | IF | CITATIONS |
|-----|---|------|-----------|
| 271 | Finding a Regulatory Balance for Genetic Biohacking. , 2021, , 157-168. | | Ο |
| 272 | Improving Commercial Genetic Data-Sharing Policy. , 2021, , 107-112. | | 0 |
| 273 | Investigative Genetic Genealogy and the Problem of Familial Forensic Identification. , 2021, , 211-228. | | 0 |
| 274 | Losing Our Minds?. , 2021, , 198-210. | | 0 |
| 275 | The Case for Remedial Germline Editing—The Long-term View. JAMA Health Forum, 2020, 1, e200241. | 1.0 | Ο |
| 276 | Antiviral Therapeutics: Key to Curbing the COVID-19 Pandemic. American Journal of Medicine, 2021, , . | 0.6 | 0 |
| 277 | Assisted Same-Sex Reproduction: The Promise of Haploid Stem Cells?. Stem Cells and Development, 2020, 29, 1417-1419. | 1.1 | Ο |
| 278 | A Divisive Ruling on Devices — Genus Medical Technologies v. FDA. New England Journal of Medicine, 2021, , . | 13.9 | 0 |
| 279 | Al reflections in 2021. Nature Machine Intelligence, 2022, 4, 5-10. | 8.3 | 0 |
| 280 | Strengthening the Power of Health Care Insurers to Regulate Medical Device Risks. , 2022, , 268-280. | | 0 |
| 281 | Digital Home Health During the COVID-19 Pandemic. , 2022, , 141-160. | | 0 |
| 282 | IP and FDA Regulation of De Novo Medical Devices. , 2022, , 117-128. | | 0 |
| 283 | <scp>A "DESIâ€</scp> for Devices <scp>?</scp> ., 2022, , 129-140. | | 0 |
| 284 | Preventing Medical Device-Borne Outbreaks. , 2022, , 192-202. | | 0 |
| 285 | Compulsory Medical Device Registries. , 2022, , 229-243. | | 0 |
| 286 | Lifecycle Regulation and Evaluation of Artificial Intelligence and Machine Learning-Based Medical Devices. , 2022, , 13-21. | | 0 |
| 287 | Clouded Judgment. , 2022, , 165-178. | | 0 |
| 288 | Stamping Out the Medicaid Coverage Gap: An ACA Imperative. American Journal of Medicine, 2022, , . | 0.6 | 0 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | The CMS Vaccine Mandate at the Supreme Court: A Hippocratic Imperative. American Journal of Medicine, 2022, , . | 0.6 | 0 |
| 290 | When Is a Change Significant? The Update Problem of Apps in Medical and Behavioral Research. Ethics & Human Research, 2022, 44, 2-11. | 0.5 | 0 |